IGHE and chronic rhinosinusitis with nasal polyps: The trial conducted by Pinto et al. (2010)28 also presented limitations regarding the number of enrolled participants, emphasizing the need for a trial with a larger number of individuals.18, 30 Two other systematic reviews also pointed out the need for additional evaluation of the efficacy of anti-IgE therapy in these patients.31, 32 In addition to establishing clinical benefit, other obstacles need to be overcome for omalizumab to be officially incorporated into the effective therapy of CRSwNP.